Therefore, it was speculated that TPM1, MYL2 and MYH11 could be the targets of obesity-induced cardiomyopathy, thus providing a theoretical basis for future drug development. The gene discussed is TPM1; the disease is obesity due to melanocortin 4 receptor deficiency.